Artoss completed a funding round of Unsecured Convertible Notes. The round began in 2017 with a US $0.5MM target and was oversubscribed to twice that, totalling $1MM. The company seeks to expand its distribution network for NanoBone® Bone Graft. Its SBX Putty format received FDA 510(k) marketing clearance in 2016, and NanoBone® QD bone graft launched in 2017. The latter comprises NanoBone SBX putty in an application designed for quick delivery.
Funds will support the development of additional NanoBone Bone Graft products for the U.S. market, regulatory requirements and commercialization.
Sources: Artoss, Inc.; ORTHOWORLD Inc.
Artoss completed a funding round of Unsecured Convertible Notes. The round began in 2017 with a US $0.5MM target and was oversubscribed to twice that, totalling $1MM. The company seeks to expand its distribution network for NanoBone® Bone Graft. Its SBX Putty format received FDA 510(k) marketing clearance in 2016,...
Artoss completed a funding round of Unsecured Convertible Notes. The round began in 2017 with a US $0.5MM target and was oversubscribed to twice that, totalling $1MM. The company seeks to expand its distribution network for NanoBone® Bone Graft. Its SBX Putty format received FDA 510(k) marketing clearance in 2016, and NanoBone® QD bone graft launched in 2017. The latter comprises NanoBone SBX putty in an application designed for quick delivery.
Funds will support the development of additional NanoBone Bone Graft products for the U.S. market, regulatory requirements and commercialization.
Sources: Artoss, Inc.; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
